A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults

This study has been terminated.
(Business Decision (see below))
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT01078376
First received: February 26, 2010
Last updated: June 26, 2014
Last verified: June 2014

February 26, 2010
June 26, 2014
May 2010
July 2013   (final data collection date for primary outcome measure)
  • Area Under the Plasma Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC[0-tlqc]) for TAK-536 [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
    AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).
  • Area Under the Plasma Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC[0-tlqc]) for TAK-536 Metabolite M-II. [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
    AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).
  • Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) for TAK-536 [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
    Area under the plasma concentration-time curve from time 0 to infinity, calculated as AUC(0-inf)=AUC(0-tlqc) + Clast/λz.
  • Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) for TAK-536 Metabolite M-II [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
    Area under the plasma concentration-time curve from time 0 to infinity, calculated as AUC(0-inf)=AUC(0-tlqc) + Clast/λz.
  • Maximum Observed Plasma Concentration (Cmax) for TAK-536 [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
    Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.
  • Maximum Observed Plasma Concentration (Cmax) for TAK-536 Metabolite M-II [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
    Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.
  • Time to Reach Cmax (Tmax) for TAK-536 [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
    Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax, as observed on Day 1.
  • Time to Reach Cmax (Tmax) for TAK-536 Metabolite M-II [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
    Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax, as observed on Day 1.
  • Terminal Elimination Half-life (T1/2) for TAK-536 [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
    Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.
  • Terminal Elimination Half-life (T1/2) for TAK-536 Metabolite M-II [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
    Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.
  • Apparent Oral Clearance (CL/F) for TAK-536 [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
    CL/F is apparent clearance of the drug from the plasma, expressed in L/hr.
  • Total Amount of Drug Excreted in Urine From Time 0 to 24 Hours Postdose (Ae[0-t]) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536) [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Total Amount of Drug Excreted in Urine From Time 0 to 24 Hours Postdose (Ae[0-t]) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II) [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Fraction of Unchanged Drug Excreted in Urine From 0 to 24 Hours Postdose (Fe%) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536) [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
    Fe=[Ae(0-24)/dose]×100 (molecular weight adjusted for metabolites.
  • Fraction of Unchanged Drug Excreted in Urine From 0 to 24 Hours Postdose (Fe%) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II) [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
    Fe=[Ae(0-24)/dose]×100 (molecular weight adjusted for metabolites.
  • Renal Clearance (CLr) From 0 to 24 Hours Postdose (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536) [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
    Renal clearance, calculated as CLr=Ae(0-24)/AUC(0-24).
  • Renal Clearance (CLr) From 0 to 24 Hours Postdose (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II) [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
    Renal clearance, calculated as CLr=Ae(0-24)/AUC(0-24).
  • Area under the plasma concentration-time curve from time 0 to time of last quantifiable concentration (AUC[0-tlqc]) for TAK-536 [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time 0 to time of last quantifiable concentration (AUC[0-tlqc]) for TAK-536 metabolite M-II. [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time 0 to infinity (AUC[0-inf]) for TAK-536 [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Area under the plasma concentration-time curve from time 0 to infinity (AUC[0-inf]) for TAK-536 metabolite M-II [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Apparent oral clearance (CL/F) (TAK-536 only, assuming complete conversion from TAK-491 to TAK-536) [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Maximum observed plasma concentration (Cmax) for TAK-536 metabolite M-II [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Time to reach Cmax (Tmax) for TAK-536 [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Time to reach Cmax (Tmax) for TAK-536 metabolite M-II [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Terminal elimination half-life (T1/2) for TAK-536 [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Terminal elimination half-life (T1/2) for TAK-536 metabolite M-II [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Maximum observed plasma concentration (Cmax) for TAK-536 [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Total Amount of Drug Excreted in Urine From Time 0 to 24 Hours Postdose (Ae[0-t]) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536) [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Total Amount of Drug Excreted in Urine From Time 0 to 24 Hours Postdose (Ae[0-t]) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II) [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Fraction of unchanged drug excreted in urine from 0 to 24 hours postdose (Fe%) (for Cohorts 1 and 2 urine pharmacokinetic endpoint for TAK-536) [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Fraction of unchanged drug excreted in urine from 0 to 24 hours postdose (Fe%) (for Cohorts 1 and 2 urine pharmacokinetic endpoint for TAK-536 metabolite M-II) [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Renal clearance (CLr) from 0 to 24 hours postdose (for Cohorts 1 and 2 urine pharmacokinetic endpoint for TAK-536) [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Renal clearance (CLr) from 0 to 24 hours postdose (for Cohorts 1 and 2 urine pharmacokinetic endpoint for TAK-536 metabolite M-II) [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01078376 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults
A Comparative Single-Dose Pharmacokinetic and Safety Study of TAK-491 Between Infants, Children, and Adolescents With Hypertension and Healthy Adults

The purpose of this study was to assess the pharmacokinetics (PK) and safety of a single dose of azilsartan medoxomil in children with hypertension, and comparative PK in healthy adults.

Within the past 10 years, the incidence of high blood pressure (hypertension) in children and adolescents has increased all over the world. This increase is connected in part to a growing number of people who are overweight and do not eat right or exercise enough. In younger children though, high blood pressure is a common consequence of underlying diseases, such as renal diseases.

This study looked at a blood pressure medicine called TAK-491 (azilsartan medoxomil) to see how it works in children who have hypertension. Azilsartan medoxomil is a prodrug that converts into TAK-536 (azilsartan), a blood pressure lowering medicine that had not been tested in children.

To be eligible to take part in this study, children with a diagnosis of hypertension (primary or secondary) must have been between the ages of 1 year and 16 years old (up to their 17th birthday). Each child was given one dose of azilsartan medoxomil, followed by a number of blood tests and assessments within 24 hours after taking azilsartan medoxomil to see how the medication is working. Adults who do not have hypertension also took part in this study to provide comparison.

This study took place in 9 sites in the UK and USA. A total of 20 children with hypertension and 9 adults without hypertension participated in this study.

This study lasted about 43 days. This included a 28 day screening period, a 2 day treatment phase and a follow up period. Each participant taking part in this study may have been requested to remain in a hospital for one overnight stay during the course of the study. Each participant was contacted by telephone 6 days and 15 days after taking azilsartan medoxomil.

Takeda has decided to close Cohort 3 (participants between 1 and 6 years of age with hypertension) enrollment early and end this study with the agreement of both the US Food and Drug Administration (FDA) and the Pediatric Committee (PDCO) at the European Medicines Agency. Requests to the FDA and PDCO were submitted to close the study without completion of enrollment in Cohort 3 due to difficulty enrolling this particular patient population. Takeda proposed an alternative option to collect PK data in this age subset by utilizing PK modeling to determine the appropriate doses in children 1-5 years of age in lieu of completing Cohort 3. The FDA and PDCO agreed with this approach.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Hypertension
  • Drug: Azilsartan medoxomil (TAK-491)
    Azilsartan medoxomil 80 mg, tablets, orally, one day only
    Other Name: TAK-491
  • Drug: Azilsartan medoxomil (TAK-491)
    Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
    Other Name: TAK-491
  • Drug: Azilsartan medoxomil (TAK-491)
    Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only
    Other Name: TAK-491
  • Experimental: Cohort 1: Healthy Adults (18 years to 45 years old)
    Azilsartan medoxomil 80 mg, tablets, orally, one day only
    Intervention: Drug: Azilsartan medoxomil (TAK-491)
  • Experimental: Cohort 1: Adolescents (≥12 to <17 years old)
    Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
    Intervention: Drug: Azilsartan medoxomil (TAK-491)
  • Experimental: Cohort 2: Children (≥6 to <12 years old)
    Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
    Intervention: Drug: Azilsartan medoxomil (TAK-491)
  • Experimental: Cohort 3: Children (≥1 to <6 years old)
    Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only
    Intervention: Drug: Azilsartan medoxomil (TAK-491)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
29
September 2013
July 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

For Pediatric Participants:

Must have a diagnosis of hypertension (SBP and/or DBP ≥95th percentile for age/gender/height).

  • For Cohorts 1 and 2 only, is within the weight range of 20 kg (44 pounds) to 100 kg (220 pounds), inclusive, at Screening.
  • For Cohort 3 only, weighs at least 8.0 kg (17.6 pounds) at Screening.
  • Participants greater than or equal to 6 years of age must have the ability to swallow a tablet of the size 6.0 millimeter diameter and 3.5 millimeter thickness.
  • Has no known history of hepatitis B, hepatitis C, and human immunodeficiency virus.
  • For Cohort 3 only, may be renal transplant patient if all other inclusion and none of the exclusion criteria are met, along with additional criteria.
  • Must have been at a constant weight, or expected weight gain for that particular age, for 30 days with no change to the dose of their diuretic drugs.

For Healthy Adult Participants:

  • Weighs at least 50 kilograms (110 pounds) and has a screening body mass index between 18 and 32 kilograms/m2, inclusive.
  • Is in good health as determined by the physician
  • Has a negative test result for hepatitis B surface antigen and antibody to hepatitis C virus, and has no known history of human immunodeficiency virus.
  • Must have a negative urine test result for selected substances of abuse .
  • Has a diastolic blood pressure between 60 and 90 mm Hg, inclusive, and a systolic blood pressure between 100 and 140 mm Hg, inclusive.

For All Participants:

  • Females of child bearing potential who are sexually active, as well as sexually active male participants, agree to routinely use adequate contraception from Screening until 30 days after receiving the last dose of study medication.
  • Has clinical laboratory results within the reference range for the testing laboratory unless the results are deemed not clinically significant by the investigator.

Exclusion Criteria:

For Pediatric Participants:

  • Is currently treated with more than 2 antihypertensive agents.
  • Has sitting trough clinic systolic blood pressure greater than 15 mm Hg or diastolic blood pressure greater than 10 mm Hg above the 99th percentile for age, gender, and height at Check-in .
  • Has renovascular disease affecting both kidneys or a solitary kidney, dialysis treatment, severe nephrotic syndrome and not in remission.
  • For Cohort 1 and 2 only, a previous renal transplant.
  • Has a creatinine clearance less than 30 mL/min/1.73 m2.

For all participants:

  • Has previously received azilsartan or azilsartan medoxomil.
  • Has a known hypersensitivity or allergy to any angiotensin type II receptor blockers or to any of the excipients in the azilsartan medoxomil formulation to be taken.
  • Has a history or clinical manifestations of severe cardiovascular disease, psychiatric disease, and any conditions that would interfere with gastrointestinal absorption.
  • Has hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease, cardiomyopathy, or uncorrected coarctation of the aorta.
  • Has been diagnosed with malignant or accelerated hypertension.
  • Has severe hepatic impairment.
  • Has a serum albumin less than 2.5 g/dL.
  • Has a glycosylated hemoglobin value greater than 8.5%.
  • Has alanine aminotransferase, aspartate aminotransferase greater than 2 times the upper limit of normal, or total bilirubin greater than 1.5 times the upper limit of normal, active liver disease, or jaundice.
  • Has hyperkalemia as defined by the laboratory normal reference range or any pertinent electrolyte disorders.
  • Is participating in another investigational study or has taken an investigational drug within 30 days prior to Check-in .
  • Has a history of drug abuse or a history of alcohol abuse within 1 year prior to study Check-in.
  • Has a history of abdominal surgery or thoracic or nonperipheral vascular surgery within 6 months prior to study Check-in.
  • Has a history of cancer, other than basal cell carcinoma or stage I squamous cell carcinoma of the skin that has not been in remission for at least 5 years prior to study Check-in.
  • Has taken any cytotoxic drugs within 12 months prior to study Check-in .
  • Has a history or presence of a clinically significant abnormal 12-lead electrocardiogram as determined by the investigator or sponsor/designee.
  • Has poor peripheral venous access.
  • Has any other condition or prior therapy that, in the opinion of the investigator, would make the participant unsuitable for the study.
  • Has taken or requires the use of any medications, supplements, or food products within the stated time periods, including:

    • Pediatric participants taking angiotensin-converting enzyme inhibitors and other angiotensin II receptor blockers will be required to withhold these medications from the morning of Day -1 until the 24 hour pharmacokinetic sample is completed on Day 2.
    • Only pediatric participants will be allowed to take medications for primary renal or urologic conditions or hypertension as long as they have been on a stable dose of their medication for at least 30 days prior to Check-in (Day -1) and those medications are not potent cytochrome P-450 inhibitors or inducers.
    • Nutraceuticals including herbal or dietary preparations such as ginseng, kava kava, and ginkgo biloba.
    • Over-the-counter medications.
    • Vitamin supplements except for pediatric participants only.
    • Alcohol-containing products.
    • Products that contain caffeine or xanthine-related compounds.
    • Foods or beverages containing grapefruit juice or Seville-type oranges.
Both
1 Year to 45 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States,   United Kingdom
 
NCT01078376
TAK-491_109, 2009-013165-25, U1111-1113-4416
Yes
Takeda
Takeda
Not Provided
Study Director: Medical Director Takeda
Takeda
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP